{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:58:54Z","timestamp":1789729134832,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015077","name":"Wydzia\u0142 Lekarski, Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["N41\/DBS\/000682"],"award-info":[{"award-number":["N41\/DBS\/000682"]}],"id":[{"id":"10.13039\/100015077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Residual pulmonary vascular obstruction (RPVO) is common following pulmonary embolism (PE) but its association with fibrin clot properties is poorly understood. We investigated whether prothrombotic state and hypofibrinolysis markers can identify patients with RPVO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In 79 normotensive noncancer patients (aged 56\u2009\u00b1\u200913.3 years) with acute PE, we determined fibrin clot permeability (K<jats:sub>s<\/jats:sub>), clot lysis time (CLT), endogenous thrombin potential (ETP), fibrinolysis proteins, oxidative stress markers, and E-selectin on admission before initiation of anticoagulant therapy, after 5\u20137 days, and 3 months of anticoagulation. RPVO was diagnosed using computed tomography angiography 3\u20136 months since PE.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with RPVO (n\u2009=\u200923, 29.1%) had at baseline higher simplified Pulmonary Embolism Severity Index (sPESI) (P\u2009=\u20090.004), higher N-terminal brain natriuretic propeptide (P\u2009=\u20090.006) and higher D-dimer (P\u2009=\u20090.044). Patients with versus without RPVO had lower K<jats:sub>s<\/jats:sub> (P\u2009&lt;\u20090.001) and longer CLT (P\u2009&lt;\u20090.05), both at baseline and 5\u20137 days since admission, but not at 3 months. Patients with RPVO showed 40.6% higher E-selectin (P\u2009&lt;\u20090.001) solely at 3 months. By multivariable logistic regression, baseline K<jats:sub>s<\/jats:sub> (odds ratio [OR] 0.010, 95% confidence interval [CI] 0.001\u20130.837, P\u2009=\u20090.042, per 10<jats:sup>\u2212\u20099<\/jats:sup> cm<jats:sup>2<\/jats:sup>), baseline D-dimer (OR 1.105, 95% CI 1.000-1.221, P\u2009=\u20090.049, per 100 ng\/ml), and E-selectin levels after 3 months (OR 3.874, 95% CI 1.239\u201312.116, P\u2009=\u20090.020, per 1 ng\/ml) were associated with RPVO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RPVO patients despite anticoagulation characterize with the formation of denser fibrin clots on admission and higher E-selectin at 3 months.\u00a0Those parameters could be the potential novel RPVO risk factors that warrant further evaluation in an independent cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s11239-023-02901-y","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T20:01:37Z","timestamp":1699300897000},"page":"248-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reduced fibrin clot permeability on admission and elevated E-selectin at 3 months as novel risk factors of residual pulmonary vascular obstruction in patients with acute pulmonary embolism"],"prefix":"10.1007","volume":"57","author":[{"given":"Konrad","family":"St\u0119pie\u0144","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Z\u0105bczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kopytek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Natorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Zalewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0667-8109","authenticated-orcid":false,"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"2901_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.thromres.2014.07.013","volume":"134","author":"D Lami","year":"2014","unstructured":"Lami D, Cellai AP, Antonucci E et al (2014) Residual perfusion defects in patients with pulmonary embolism are related to impaired fibrinolytic capacity. Thromb Res 134:737\u2013741. https:\/\/doi.org\/10.1016\/j.thromres.2014.07.013","journal-title":"Thromb Res"},{"key":"2901_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.thromres.2016.10.030","volume":"148","author":"B Planquette","year":"2016","unstructured":"Planquette B, Ferr\u00e9 A, Peron J et al (2016) Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism. A single center cohort study. Thromb Res 148:70\u201375. https:\/\/doi.org\/10.1016\/j.thromres.2016.10.030","journal-title":"Thromb Res"},{"key":"2901_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.thromres.2017.06.017","volume":"164","author":"AK Sista","year":"2018","unstructured":"Sista AK, Klok FA (2018) Late outcomes of pulmonary embolism: the post-PE syndrome. Thromb Res 164:157\u2013162. https:\/\/doi.org\/10.1016\/j.thromres.2017.06.017","journal-title":"Thromb Res"},{"key":"2901_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2020.06.004","volume":"194","author":"G Picart","year":"2020","unstructured":"Picart G, Robin P, Tromeur C et al (2020) Predictors of residual pulmonary vascular obstruction after pulmonary embolism: results from a prospective cohort study. Thromb Res 194:1\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2020.06.004","journal-title":"Thromb Res"},{"key":"2901_CR5","doi-asserted-by":"publisher","unstructured":"Undas A (2017) Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence. Biomed Res Int. ; 2017: 8196256. https:\/\/doi.org\/10.1155\/2017\/8196256","DOI":"10.1155\/2017\/8196256"},{"key":"2901_CR6","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2009-05-222380","volume":"114","author":"A Undas","year":"2009","unstructured":"Undas A, Zawilska K, Ciesla-Dul M et al (2009) Altered fibrin clot structure\/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114:4272\u20134278. https:\/\/doi.org\/10.1182\/blood-2009-05-222380","journal-title":"Blood"},{"key":"2901_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/ATVBAHA.116.308253","volume":"37","author":"M Zabczyk","year":"2017","unstructured":"Zabczyk M, Plens K, Wojtowicz W et al (2017) Prothrombotic fibrin clot phenotype is Associated with Recurrent Pulmonary Embolism after discontinuation of anticoagulant therapy. Arterioscler Thromb Vasc Biol 37:365\u2013373. https:\/\/doi.org\/10.1161\/ATVBAHA.116.308253","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2901_CR8","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1016\/j.thromres.2012.06.005","volume":"130","author":"A Undas","year":"2012","unstructured":"Undas A, Cie\u015bla-Dul M, Dr\u0105\u017ckiewicz T et al (2012) Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein(a) and apolipoprotein(a) isoform. Thromb Res 130:e184\u2013187. https:\/\/doi.org\/10.1016\/j.thromres.2012.06.005","journal-title":"Thromb Res"},{"key":"2901_CR9","doi-asserted-by":"publisher","first-page":"e13660","DOI":"10.1111\/eci.13660","volume":"52","author":"M Z\u0105bczyk","year":"2022","unstructured":"Z\u0105bczyk M, Natorska J, Janion-Sadowska A et al (2022) Isoprostane-8 and GDF-15 as novel markers of post-PE syndrome: relation with prothrombotic factors. Eur J Clin Invest 52:e13660. https:\/\/doi.org\/10.1111\/eci.13660","journal-title":"Eur J Clin Invest"},{"key":"2901_CR10","doi-asserted-by":"publisher","first-page":"1801467","DOI":"10.1183\/13993003.01467-2018","volume":"52","author":"B Planquette","year":"2018","unstructured":"Planquette B, Sanchez O, Marsh JJ et al (2018) Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment. Eur Respir J 52:1801467. https:\/\/doi.org\/10.1183\/13993003.01467-2018","journal-title":"Eur Respir J"},{"key":"2901_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/jth.15689","volume":"20","author":"M Purdy","year":"2022","unstructured":"Purdy M, Obi A, Myers D et al (2022) P- and E- selectin in venous thrombosis and non-venous pathologies. J Thromb Haemost 20:1056\u20131066. https:\/\/doi.org\/10.1111\/jth.15689","journal-title":"J Thromb Haemost"},{"key":"2901_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0022-4804(02)00041-0","volume":"109","author":"VV Sullivan","year":"2003","unstructured":"Sullivan VV, Hawley AE, Farris DM et al (2003) Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res 109:1\u20137. https:\/\/doi.org\/10.1016\/s0022-4804(02)00041-0","journal-title":"J Surg Res"},{"key":"2901_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1006\/jsre.2002.6552","volume":"108","author":"D Myers Jr","year":"2002","unstructured":"Myers D Jr, Farris D, Hawley A et al (2002) Selectins influence thrombosis in a mouse model of experimental deep venous thrombosis. J Surg Res 108:212\u2013221. https:\/\/doi.org\/10.1006\/jsre.2002.6552","journal-title":"J Surg Res"},{"key":"2901_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3892\/mmr.2012.940","volume":"6","author":"Y Xie","year":"2012","unstructured":"Xie Y, Duan Q, Wang L et al (2012) Genomic characteristics of adhesion molecules in patients with symptomatic pulmonary embolism. Mol Med Rep 6:585\u2013590. https:\/\/doi.org\/10.3892\/mmr.2012.940","journal-title":"Mol Med Rep"},{"key":"2901_CR15","doi-asserted-by":"publisher","first-page":"107602962110648","DOI":"10.1177\/10760296211064898","volume":"28","author":"I Darwish","year":"2022","unstructured":"Darwish I, Fareed J, Brailovsky Y et al (2022) Dysregulation of biomarkers of hemostatic activation and inflammatory processes are Associated with adverse outcomes in Pulmonary Embolism. Clin Appl Thromb Hemost 28:10760296211064898. https:\/\/doi.org\/10.1177\/10760296211064898","journal-title":"Clin Appl Thromb Hemost"},{"key":"2901_CR16","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1182\/blood.V88.9.3259.bloodjournal8893259","volume":"88","author":"GS Kansas","year":"1996","unstructured":"Kansas GS (1996) Selectins and their ligands: current concepts and controversies. Blood 88:3259\u20133287","journal-title":"Blood"},{"key":"2901_CR17","doi-asserted-by":"publisher","first-page":"e0227150","DOI":"10.1371\/journal.pone.0227150","volume":"15","author":"LF Bittar","year":"2020","unstructured":"Bittar LF, Silva LQD, Orsi FLA et al (2020) Increased inflammation and endothelial markers in patients with late severe post-thrombotic syndrome. PLoS ONE 15:e0227150. https:\/\/doi.org\/10.1371\/journal.pone.0227150","journal-title":"PLoS ONE"},{"key":"2901_CR18","doi-asserted-by":"publisher","first-page":"11433","DOI":"10.1038\/s41598-020-68375-7","volume":"10","author":"M Z\u0105bczyk","year":"2020","unstructured":"Z\u0105bczyk M, Natorska J, Janion-Sadowska A et al (2020) Prothrombotic fibrin clot properties associated with NETs formation characterize acute pulmonary embolism patients with higher mortality risk. Sci Rep 10:11433. https:\/\/doi.org\/10.1038\/s41598-020-68375-7","journal-title":"Sci Rep"},{"key":"2901_CR19","doi-asserted-by":"publisher","first-page":"16134","DOI":"10.20452\/pamw.16134","volume":"131","author":"P Pruszczyk","year":"2021","unstructured":"Pruszczyk P, Skowro\u0144ska M, Ciurzy\u0144ski M et al (2021) Assessment of pulmonary embolism severity and the risk of early death. Pol Arch Intern Med 131:16134. https:\/\/doi.org\/10.20452\/pamw.16134","journal-title":"Pol Arch Intern Med"},{"key":"2901_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.33963\/KP.a2022.0141","volume":"80","author":"M Ciurzy\u0144ski","year":"2022","unstructured":"Ciurzy\u0144ski M, Kurzyna M, Kope\u0107 G et al (2022) An expert opinion of the polish Cardiac Society Working Group on Pulmonary circulation on screening for chronic thromboembolic pulmonary hypertension patients after acute pulmonary embolism: update. Kardiol Pol 80:723\u2013732. https:\/\/doi.org\/10.33963\/KP.a2022.0141","journal-title":"Kardiol Pol"},{"key":"2901_CR21","doi-asserted-by":"publisher","first-page":"785246","DOI":"10.3389\/fcvm.2022.785246","volume":"9","author":"K Stepien","year":"2022","unstructured":"Stepien K, Nowak K, Szlosarczyk B et al (2022) Clinical characteristics and long-term outcomes of MINOCA accompanied by active Cancer: a retrospective insight into a Cardio-Oncology Center Registry. Front Cardiovasc Med 9:785246. https:\/\/doi.org\/10.3389\/fcvm.2022.785246","journal-title":"Front Cardiovasc Med"},{"key":"2901_CR22","doi-asserted-by":"publisher","first-page":"106567","DOI":"10.1016\/j.vph.2019.106567","volume":"120","author":"K Stepien","year":"2019","unstructured":"Stepien K, Nowak K, Zalewski J et al (2019) Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study. Vascul Pharmacol 120:106567. https:\/\/doi.org\/10.1016\/j.vph.2019.106567","journal-title":"Vascul Pharmacol"},{"key":"2901_CR23","doi-asserted-by":"publisher","first-page":"107153","DOI":"10.1016\/j.vph.2023.107153","volume":"149","author":"K St\u0119pie\u0144","year":"2023","unstructured":"St\u0119pie\u0144 K, Siudut J, Konieczy\u0144ska M et al (2023) Effect of high-dose statin therapy on coagulation factors: lowering of factor XI as a modifier of fibrin clot properties in coronary artery disease. Vascul Pharmacol 149:107153. https:\/\/doi.org\/10.1016\/j.vph.2023.107153","journal-title":"Vascul Pharmacol"},{"key":"2901_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/jth.14002","volume":"16","author":"M Pieters","year":"2018","unstructured":"Pieters M, Philippou H, Undas A et al (2018) An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost 16:1007\u20131012. https:\/\/doi.org\/10.1111\/jth.14002","journal-title":"J Thromb Haemost"},{"key":"2901_CR25","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3390\/jcm9072018","volume":"9","author":"J Zalewski","year":"2020","unstructured":"Zalewski J, Stepien K, Nowak K et al (2020) Delayed Thrombin Generation is Associated with minor bleedings in venous thromboembolism patients on Rivaroxaban: usefulness of calibrated Automated Thrombography. J Clin Med 9:2018. https:\/\/doi.org\/10.3390\/jcm9072018","journal-title":"J Clin Med"},{"key":"2901_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.thromres.2019.09.038","volume":"184","author":"PB Bonnefoy","year":"2019","unstructured":"Bonnefoy PB, Margelidon-Cozzolino V, Catella-Chatron J et al (2019) What\u2019s next after the clot? Residual pulmonary vascular obstruction after pulmonary embolism: from imaging finding to clinical consequences. Thromb Res 184:67\u201376. https:\/\/doi.org\/10.1016\/j.thromres.2019.09.038","journal-title":"Thromb Res"},{"key":"2901_CR27","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.21037\/jtd-21-403","volume":"13","author":"Y Chang","year":"2021","unstructured":"Chang Y, Moon JY, Park JH et al (2021) Predictors of residual pulmonary vascular obstruction after anticoagulation monotherapy in patients with intermediate-risk pulmonary embolism. J Thorac Dis 13:4217\u20134227. https:\/\/doi.org\/10.21037\/jtd-21-403","journal-title":"J Thorac Dis"},{"key":"2901_CR28","doi-asserted-by":"publisher","first-page":"16155","DOI":"10.20452\/pamw.16155","volume":"132","author":"A Pietrasik","year":"2022","unstructured":"Pietrasik A, G\u0105secka A, Smyk JM et al (2022) Acute-on-chronic pulmonary embolism and concomitant paradoxical embolism: two diseases, one intervention. Pol Arch Intern Med 132:16155. https:\/\/doi.org\/10.20452\/pamw.16155","journal-title":"Pol Arch Intern Med"},{"key":"2901_CR29","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.amjcard.2017.03.002","volume":"119","author":"R Chopard","year":"2017","unstructured":"Chopard R, Genet B, Ecarnot F et al (2017) Detection of residual pulmonary vascular obstruction by ventilation-perfusion lung scan late after a First Pulmonary Embolism. Am J Cardiol 119:1883\u20131889. https:\/\/doi.org\/10.1016\/j.amjcard.2017.03.002","journal-title":"Am J Cardiol"},{"key":"2901_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/eurheartj\/ehs365","volume":"34","author":"N Meneveau","year":"2013","unstructured":"Meneveau N, Ider O, Seronde MF et al (2013) Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism. Eur Heart J 34:693\u2013701. https:\/\/doi.org\/10.1093\/eurheartj\/ehs365","journal-title":"Eur Heart J"},{"key":"2901_CR31","doi-asserted-by":"publisher","first-page":"16326","DOI":"10.20452\/pamw.16326","volume":"132","author":"KW Undas","year":"2022","unstructured":"Undas KW, Siudut J, Z\u0105bczyk M (2022) Unfavorably altered fibrin clot properties are associated with recurrent venous thromboembolism in patients following postdischarge events. Pol Arch Intern Med 132:16326. https:\/\/doi.org\/10.20452\/pamw.16326","journal-title":"Pol Arch Intern Med"},{"key":"2901_CR32","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1161\/01.ATV.0000136649.83297.bf","volume":"24","author":"EM Scott","year":"2004","unstructured":"Scott EM, Ari\u00ebns RA, Grant PJ (2004) Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 24:1558\u20131566. https:\/\/doi.org\/10.1161\/01.ATV.0000136649.83297.bf","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2901_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","volume":"40","author":"JJ de Vries","year":"2020","unstructured":"de Vries JJ, Snoek CJM, Rijken DC et al (2020) Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and Fibrinolysis: a systematic review. Arterioscler Thromb Vasc Biol 40:554\u2013569. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313626","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2901_CR34","doi-asserted-by":"publisher","first-page":"103487","DOI":"10.1016\/j.jprot.2019.103487","volume":"208","author":"M Z\u0105bczyk","year":"2019","unstructured":"Z\u0105bczyk M, Stachowicz A, Natorska J et al (2019) Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time. J Proteom 208:103487. https:\/\/doi.org\/10.1016\/j.jprot.2019.103487","journal-title":"J Proteom"},{"key":"2901_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12014-017-9173-x","volume":"14","author":"A Stachowicz","year":"2017","unstructured":"Stachowicz A, Siudut J, Suski M et al (2017) Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism. Clin Proteom 14:38. https:\/\/doi.org\/10.1186\/s12014-017-9173-x","journal-title":"Clin Proteom"},{"key":"2901_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10238-021-00787-9","volume":"22","author":"MM Watany","year":"2022","unstructured":"Watany MM, Abdou S, Elkolaly R et al (2022) Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin Exp Med 22:567\u2013575. https:\/\/doi.org\/10.1007\/s10238-021-00787-9","journal-title":"Clin Exp Med"},{"key":"2901_CR37","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1160\/TH16-04-0323","volume":"117","author":"DL Culmer","year":"2017","unstructured":"Culmer DL, Dunbar ML, Hawley AE et al (2017) E-selectin inhibition with GMI-1271 decreases venous thrombosis without profoundly affecting tail vein bleeding in a mouse model. Thromb Haemost 117:1171\u20131181. https:\/\/doi.org\/10.1160\/TH16-04-0323","journal-title":"Thromb Haemost"},{"key":"2901_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jvsv.2020.12.086","volume":"10","author":"DD Myers Jr","year":"2022","unstructured":"Myers DD Jr, Ning J, Lester P et al (2022) E-selectin inhibitor is superior to low-molecular-weight heparin for the treatment of experimental venous thrombosis. J Vasc Surg Venous Lymphat Disord 10:211\u2013220. https:\/\/doi.org\/10.1016\/j.jvsv.2020.12.086","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"2901_CR39","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4:4693\u20134738. https:\/\/doi.org\/10.1182\/bloodadvances.2020001830","journal-title":"Blood Adv"},{"key":"2901_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1538-7836.2009.03293.x","volume":"7","author":"E Bruinstroop","year":"2009","unstructured":"Bruinstroop E, Klok FA, Van De Ree MA et al (2009) Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 7:611\u2013618. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03293.x","journal-title":"J Thromb Haemost"},{"key":"2901_CR41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.thromres.2007.08.020","volume":"122","author":"A Kaczy\u0144ska","year":"2008","unstructured":"Kaczy\u0144ska A, Kostrubiec M, Pacho R et al (2008) Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6 months anticoagulation after the first episode of acute pulmonary embolism. Thromb Res 122:21\u201325. https:\/\/doi.org\/10.1016\/j.thromres.2007.08.020","journal-title":"Thromb Res"},{"key":"2901_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.thromres.2021.02.033","volume":"202","author":"C Aranda","year":"2021","unstructured":"Aranda C, Peralta L, Gagliardi L et al (2021) A significant decrease in D-dimer concentration within one month of anticoagulation therapy as a predictor of both complete recanalization and risk of recurrence after initial pulmonary embolism. Thromb Res 202:31\u201335. https:\/\/doi.org\/10.1016\/j.thromres.2021.02.033","journal-title":"Thromb Res"},{"key":"2901_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.33963\/KP.a2021.0180","volume":"80","author":"J Wili\u0144ski","year":"2022","unstructured":"Wili\u0144ski J, Skwarek A, Borek R et al (2022) Right ventricular wall thickness indexed to body surface area as an echocardiographic predictor of acute pulmonary embolism in high-risk patients. Kardiol Pol 80:205\u2013207. https:\/\/doi.org\/10.33963\/KP.a2021.0180","journal-title":"Kardiol Pol"},{"key":"2901_CR44","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.33963\/KP.a2021.0164","volume":"79","author":"A Delluc","year":"2021","unstructured":"Delluc A, Wang TF (2021) How to treat incidental pulmonary embolism in cancer patients? Recent advances. Kardiol Pol 79:1305\u20131310. https:\/\/doi.org\/10.33963\/KP.a2021.0164","journal-title":"Kardiol Pol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-023-02901-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-023-02901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:21:13Z","timestamp":1708014073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-023-02901-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,6]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["2901"],"URL":"https:\/\/doi.org\/10.1007\/s11239-023-02901-y","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,6]]},"assertion":[{"value":"24 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}